Immunohistochemical profiles of brain metastases from breast cancer
作者： Kan Yonemori , Koji Tsuta , Chikako Shimizu , Yutaka Hatanaka , Kaoru Hashizume
DOI: 10.1007/S11060-008-9654-X
关键词:
摘要: The aim of present study is to explore the immunohistochemical profiles brain metastases from breast cancer. We retrospectively performed staining for estrogen receptor (ER), progesterone (PgR), human epidermal growth factor type 2 (HER2/neu), and cytokeratin (CK) 5/6 in 29 patients with resected tumor specimens metastases. Immunohistochemical ER, PgR HER2/neu was 24 primary tumors. positive frequency PgR, HER2/neu, CK5/6, were 13.8%, 6.9%, 37.9%, 24.1%, respectively. including metastasis differed seven (29.2%, N = 7/24). Interestingly, biological characteristics sometimes changed which represented by staining. Therefore, changes features cancer should be taken into account when developing treatment strategies, new molecular-targeted drugs,
springer.com
sci-hub.se 参考文章(31)
Jennet M. Harvey, Gary M. Clark, C. Kent Osborne, D. Craig Allred, Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer Journal of Clinical Oncology. ,vol. 17, pp. 1474- 1474 ,(1999) , 10.1200/JCO.1999.17.5.1474
David G Hicks, Sarah M Short, Nichole L Prescott, Shannon M Tarr, Kara A Coleman, Brian J Yoder, Joseph P Crowe, Toni K Choueiri, Andrea E Dawson, G Thomas Budd, Raymond R Tubbs, Graham Casey, Robert J Weil, None, Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. The American Journal of Surgical Pathology. ,vol. 30, pp. 1097- 1104 ,(2006) , 10.1097/01.PAS.0000213306.05811.B9
C Kamby, B Bruun Rasmussen, B Kristensen, Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. British Journal of Cancer. ,vol. 60, pp. 252- 257 ,(1989) , 10.1038/BJC.1989.264
Nancy U. Lin, Jennifer R. Bellon, Eric P. Winer, CNS Metastases in Breast Cancer Journal of Clinical Oncology. ,vol. 22, pp. 3608- 3617 ,(2004) , 10.1200/JCO.2004.01.175
Aurel Perren, Liang-Ping Weng, Alexander H. Boag, Ulricke Ziebold, Kosha Thakore, Patricia L.M. Dahia, Paul Komminoth, Jacqueline A. Lees, Lois M. Mulligan, George L. Mutter, Charis Eng, Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast American Journal of Pathology. ,vol. 155, pp. 1253- 1260 ,(1999) , 10.1016/S0002-9440(10)65227-3
Yee-Lu Tham, Krystal Sexton, Rita Kramer, Susan Hilsenbeck, Richard Elledge, Primary breast cancer phenotypes associated with propensity for central nervous system metastases Cancer. ,vol. 107, pp. 696- 704 ,(2006) , 10.1002/CNCR.22041
Rita Nahta, Dihua Yu, Mien-Chie Hung, Gabriel N Hortobagyi, Francisco J Esteva, Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer Nature Reviews Clinical Oncology. ,vol. 3, pp. 269- 280 ,(2006) , 10.1038/NCPONC0509
Benjamin D. L. Li, A. Byskosh, Rosemary B. Duda, A. Molteni, Estrogen and progesterone receptor concordance between primary and recurrent breast cancer Journal of Surgical Oncology. ,vol. 57, pp. 71- 77 ,(1994) , 10.1002/JSO.2930570202
Louis P. Pertschuk, Constantine A. Axiotis, Joseph G. Feldman, Yong‐Doo Kim, Sebastian J. Karavattayhayyil, Lorraine Braithwaite, Marked Intratumoral Heterogeneity of the Proto-Oncogene Her-2/neu Determined by Three Different Detection Systems. Breast Journal. ,vol. 5, pp. 369- 374 ,(1999) , 10.1046/J.1524-4741.1999.97088.X
S. Tsutsui, S. Ohno, S. Murakami, A. Kataoka, J. Kinoshita, Y. Hachitanda, EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. Ejso. ,vol. 28, pp. 383- 387 ,(2002) , 10.1053/EJSO.2002.1259